

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

#### **Application Number** 09/807,047 Filing Date **TRANSMITTAL** June 25, 2002 First Named Inventor **FORM** Jerry PELLETIER Art Unit 1634 (to be used for all correspondence after initial filing) Examiner Name F. Lu Attorney Docket Number 514012000100

Total Number	TOF Pages III This Submiss	6			314012000100
ENCLOSURES (Check all that apply)					
Fee Transn	nittal Form	Drawing(s)			After Allowance Communication to Group
Fee Attached		Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences
Amendment/Reply		Petition			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final		Petition to Convert to a Provisional Application			Proprietary Information
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address			Status Letter
Extension of Time Request		Terminal Disclaimer		x	Other Enclosure(s) (please identify below):
Express Abandonment Request		Request for Refund  CD, Number of CD(s)		Request for Corrected Filing Receipt (2 pages)     Marked up copy of Filing Receipt (2 pages)     Application Data Sheet (2 pages)	
Information Disclosure Statement					
Certified Copy of Priority Document(s)				4. WC	Copy of first page of PCT Publication 0 00/20630 (1 page) Return receipt postcard
Response to Missing Parts/ Incomplete Application		Remarks			
Response to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm or Individual name	MORRISON & FOERSTER LLP Kimberly A. Bolin - 44,546 for CUSTOMER NUMBER: 25226 Gladys H. Monroy – 32,430				R NUMBER: <b>25226</b>
Signature Signature					
Date March 9, 2004					
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.					

Signature: Derwie Luce

'I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22333-1450, on the date shown below.

Docket No.: 514012000100

(PATENT)

Dated: 319 04

MAR 1 2 2004

Signature: MUNION (Denise M. Lade)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Patent Application of:

In a TRIVETTY PELLETIER et al.

Application No.: 09/807,047

Confirmation No.: 2183

Filed: June 25, 2002

Art Unit: 1634

For: OLIGONUCLEOTIDE PRIMERS THAT DESTABILIZE NON-SPECIFIC DUPLEX

Examiner: F. Lu

FORMATION AND USES THEREOF

### REQUEST FOR CORRECTED FILING RECEIPT

Filing Receipt Corrections
Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the aboveidentified patent application. The corrections to be made to the Filing Receipt are as follows:

- 1. In Atty Docket No. field, please delete "Goudreau" and insert --514012000100--;
- 2. In Applicant(s) field, please delete "QC" and insert --Quebec--;
- 3. In Applicant(s) field, second line, before Quebec, please insert --Montreal,--; and
- 4. In Domestic Priority data as claimed by applicant, please delete "11/06/1999" and insert --10/06/1999--.

Applicants enclose an initial Application Data Sheet reflecting updated Atty Docket No, address of inventors, and correct International Filing Date; copies of the marked-up Filing Receipt and a copy of the first page of PCT Publication WO 00/20630 (PCT/CA99/00933) showing the date of October 6, 1999 as the International Filing Date and October 7, 1998 as the Priority Date Claimed.

Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Applicants inadvertently listed an incorrect International Filing Date and Priority Date Claimed on the initial Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C. § 371 April 6, 2001. The correct dates should be OCTOBER 6, 1999 and OCTOBER 7, 1998, respectively. The typographical error is obvious due to the fact that the International Application Published under the Patent Cooperation Treaty clearly states the dates above. This error should not affect the filing in any way.

In the unlikely event that the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 514012000100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 9, 2004

Respectfully submitted,

Kimberly A. Bolin

Registration No.: 44,546

For

Gladys H. Monroy

Registration No. 32,430

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304

(650) 813-5711





Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING DATE

**GRP ART UNIT** 

FIL FEE REC'D

ATTY.DOCKET.NO

DRAWINGS

TOT CLAIMS IND CLAIMS

09/807,047

06/25/2002

1645

999

Goudreau

8

514012000100

36

**CONFIRMATION NO. 2183** 

12

Gladys H Monroy Morrison & Foerster 755 Page Mill Road Palo Alto, CA 94304-101

SEP 2 4 2002

MORRISON & FOERSTER, ILP



Date Mailed: 09/17/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Quebec

Jerry Pelletier, Baie D'Urfee, QC, CANADA; Manjula Das, Quebec, CANADA;

Montreal.

Domestic Priority data as claimed by applicant

10/06/1999

THIS APPLICATION IS A 371 OF PCT/CA99/00933 11/06/1999

Foreign Applications

CANADA 2,246,623 10/07/1998

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

**Title** 

Oligonucleotide primers that destabilize non-specific duplex formation and uses thereof

Preliminary Class

DOCKETER

MAR 1 2 2004 2004

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

# MAR 1 2 2004 JULY STRADENIES

### Application Data Sheet

# **Application Information**

Application Type:: Regular

Subject Matter:: Utility

Suggested Group Art Unit:: 1634

CD-ROM or CD-R?:: None

Sequence submission?:: None

Computer Readable Form (CRF)?:: No

Title:: OLIGONUCLEOTIDE PRIMERS THAT

DESTABILIZE NON-SPECIFIC DUPLEX

FORMATION AND USES THEREOF

Attorney Docket Number:: 514012000100

Request for Early Publication?:: No

Request for Non-Publication?:: No

Suggested Drawing Figure:: 2

Total Drawing Sheets:: 8

Small Entity?:: No

Petition included?:: No

Secrecy Order in Parent Appl.?:: No

#### **Applicant Information**

Applicant Authority Type:: Inventor

Primary Citizenship Country:: Canada

Status:: Full Capacity

Given Name:: Jerry

Family Name:: PELLETIER

City of Residence:: Baie D'urfee

Country of Residence:: Canada

Street of mailing address:: 8 Lakeview

City of mailing address:: Baie D'urfee

State or Province of mailing address:: Quebec

Country of mailing address::

Canada

Postal or Zip Code of mailing address::

H9X 3B1

Applicant Authority Type::

Inventor

Primary Citizenship Country::

Canada

Status::

**Full Capacity** 

Given Name::

Manjula

Family Name::

DAS

City of Residence::

Montreal

Country of Residence::

Canada

Street of mailing address::

3484 Stanley, Apt. 205

City of mailing address::

Montreal

State or Province of mailing address::

Quebec

Country of mailing address::

Canada

Postal or Zip Code of mailing address::

H3A 1S1

# **Correspondence Information**

Correspondence Customer Number::

25226

#### Representative Information

Representative Customer Number::

25226

#### **Domestic Priority Information**

Application::

Continuity Type::

Parent Application::

Parent Filing Date::

This Application

National Phase of

PCT/CA99/00933

10/6/99

### **Foreign Priority Information**

Country::

Application number::

FilingDate::

Priority Claimed::

Canada

2,246,623

10/7/98

Yes

# LECTUAL PROPERTY ORGANIZATION



INTERNATIONAL APPL TION PURSIGHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification

C12Q 1/68

(11) International Publication Number:

WO 00/20630

(43) International Publication Date:

13 April 2000 (13.04.00)

(21) International Application Number:

PCT/CA99/00933

A1

(22) International Filing Date:

6 October 1999 (06.10.99)

(30) Priority Data:

2,246,623

7 October 1998 (07.10.98)

CA

(71) Applicant (for all designated States except US): MCGILL UNIVERSITY [CA/CA]; 3550 University Street, Montreal, Quebec H3A 2A7 (CA).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): PELLETIER, Jerry [CA/CA]; 8 Lakeview, Baie D'Urfée, Quebec H9X 3B1 (CA). DAS, Manjula [IN/CA]; Apartment #205, 3484 Stanley, Montreal, Quebec H3A 1S1 (CA).
- (74) Agents: DUBUC, Jean et al.; Goudreau Gage Dubuc & Martineau Walker, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR. BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: OLIGONUCLEOTIDE PRIMERS THAT DESTABILIZE NON-SPECIFIC DUPLEX FORMATION AND USES THEREOF

#### (57) Abstract

The present invention relates to the demonstration that a modification of a homopolymeric stretch in an oligonucleotide, or primer, improves the discrimination for binding of such a modified oligonucleotide or primer to its complementary homopolymeric target sequence, as compared to a non-homopolymeric sequence. More specifically, an oligo d(T) primer having two of the thymine bases substituted by 3-nitropyrrole were used in a poly A primed cDNA synthesis experiment to demonstrate an improvement in discrimination between the priming of cDNA synthesis from bona fide poly A sequence as compared to internal A-rich sequences. The present invention relates to modifications of homopolymeric sequences in oligos, decreasing the ridging bonding capacity, in general, since other modifications, such as an oligo d(T) primer substituted with 2' deoxyinosine was also shown to improve the discrimination between the binding to a bona fide poly A tail as compared to A-rich sequences. The present invention thus relates to universal primers which reduce mispriming during cDNA library construction, thereby increasing the proportion of cDNA clones having been primed from the bona fide 3' poly A tail. The present invention further relates to the use of the discriminating oligonucleotides of the present invention in other methods such as mRNA purification, PCR-based detection methods and sequencing.

Internal A-rich Stretch Poly (A) Tail laaaaaaacaaaaagaaaaaaaaa aaaaaaaaaaaaaaa... umuimuimum unununununun ' Tm stable at 37°C -anneals. Tm stable at 37°C -anneals.



 $Z = 1 - (2' - Deoxy - \beta - D - Ribofuranosyl) -$ 3-Nitropyrrole

В

Oligo d(T) · Z Primer:

Е

Internal A-rich Stretch Poly (A) Tail llaaaaaaacaaaaagaaaaaaaa tttttttttttttttt tittizttttttttttttttttttt  $T_m$  unstable at 37°C - does not anneal.  $T_m$  stable at 37°C -anneals.